Chipscreen(SH:688321) Zhi Tong Cai Jing·2026-01-26 11:24Core Viewpoint - Microchip Biotech (688321.SH) forecasts a net profit of approximately 53.46 million yuan for the year 2025, marking an increase of about 168.03 million yuan compared to the previous year, thus achieving a turnaround from loss to profit [1] Group 1: Financial Performance - The company expects a net profit attributable to shareholders of approximately 53.46 million yuan for 2025, which represents a year-on-year increase of about 168.03 million yuan [1] - The company's revenue is projected to grow significantly, driven by the commercial success of its products [1] Group 2: Product Performance - The product Siglecatinib has shown remarkable commercial effectiveness, with sales revenue increasing by approximately 123% year-on-year due to its unique clinical value in "diabetes liver management" and the expansion of self-operated, strategic partnerships, and new retail channels [1] - The product Sidabenamine has gained recognition in the market and support from the National Healthcare Security Administration, with a new indication for diffuse large B-cell lymphoma included in the National Medical Insurance Directory in January 2025, contributing to a year-on-year sales revenue growth of about 16% [1]